The purpose of the Psychiatric Genomics Consortium (PGC) is to unite investigators around the world to conduct meta- and mega-analyses of genome-wide genomic data for psychiatric disorders.
"Genome-wide association dataset for meta-analysis consisting of 2,960 individual childhood ADHD cases plus parental or independent control samples"
"Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases."
Combined genome-wide association study (GWAS) of 7,481 individuals with bipolar disorder (cases) and 9,250 controls as part of the Psychiatric GWAS Consortium
"We analysed genome-wide single-nucleotide polymorphism (SNP) data for the five disorders in 33,332 cases and 27,888 controls of European ancestory."
In the discovery phase, more than 1.2 million autosomal and X chromosome single-nucleotide polymorphisms (SNPs) were analyzed in 18 759 independent and unrelated subjects of recent European ancestry (9240 MDD cases and 9519 controls).
Genome-wide association study that in stage 1 discovery comprised 21,856 individuals of European ancestry and a stage 2 replication sample of 29,839 independent samples.
"We report the results of a multi-stage schizophrenia genome-wide association study of up to 36,989 cases and 113,075 controls. We obtained genome-wide genotype data from which we constructed 49 ancestry matched, non-overlapping case-control samples (46 of European and three of East Asian ancestry, 34,241 cases and 45,604 controls) and 3 family-based samples of European ancestry (1,235 parent affected-offspring trios). These samples comprise the primary PGC GWAS meta-analysis."
"These data are from a meta-analysis of the Sweden 1-6 schizophrenia case-control study with the 2011 PGC SCZ report. Imputation is to 1000 Genomes, and there are 9.8M autosomal SNPs."